Results 181 to 190 of about 21,018 (198)

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation

Cancer Discovery, 2018
Bonnie K Harrington, Kerry A Rogers, Farrukh T Awan   +2 more
exaly  

Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

Lancet Oncology, The, 2019
Carol Moreno, Richard F Greil, Fatih Demirkan   +2 more
exaly  

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

Nature Medicine, 2015
Ryan M Young, Stefania Pittaluga, George W Wright   +2 more
exaly  

Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study

Lancet Oncology, The, 2016
Fatih Demirkan, Jiri Mayer, Nancy L Bartlett   +2 more
exaly  

Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study

Journal of Clinical Oncology, 2019
Peter Hillmen, Chris Fegan, Anna Schuh
exaly  

Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase

Circulation, 2020
Ling Xiao, Joe-Elie Salem, Sebastian Clauss   +2 more
exaly  

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

Leukemia, 2019
Jan A Burger, Paul M Barr, Tadeusz Robak
exaly  

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

Lancet Oncology, The, 2015
Janet Valdez, Georg Aue, Nakhle S Saba
exaly  

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study

Lancet Oncology, The, 2016
Jeffrey A Jones, Anthony R Mato, Peter Hillmen   +2 more
exaly  

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2013
John C Byrd, Ian W Flinn, Jan A Burger
exaly